Semin Respir Crit Care Med 2018; 39(03): 399-410
DOI: 10.1055/s-0038-1651490
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Management of Extrapulmonary Nontuberculous Mycobacterial Infections

Michael R. Holt
1   Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado
2   Department of Medicine, University of Colorado Denver, Aurora, Colorado
,
Shannon Kasperbauer
1   Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado
2   Department of Medicine, University of Colorado Denver, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
02 August 2018 (online)

Abstract

Extrapulmonary disease occurs in a minority of nontuberculous mycobacterial (NTM) infections. The pattern of disease tends to be multifocal in immunocompromised individuals and localized in the immunocompetent. There is increasing recognition of disseminated Mycobacterium chimaera infection, as a complication of cardiac surgery, and focal infections due to rapidly growing mycobacteria. Microbiologic diagnosis requires detection of NTM in blood or tissue samples by microscopy, culture, or molecular methods. Management of extrapulmonary NTM infection requires prolonged, targeted multiple-drug therapy and, in some cases, aggressive surgical intervention. The optimal treatment approach is often unknown. Despite combined medical and surgical therapy, outcomes may be poor. A high degree of clinical suspicion and early diagnosis are required to maximize chances of a positive outcome.

 
  • References

  • 1 Griffith DE, Aksamit T, Brown-Elliott BA. , et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 (04) 367-416
  • 2 Lai CC, Tan CK, Chou CH. , et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010; 16 (02) 294-296
  • 3 van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010; 14 (09) 1176-1180
  • 4 Hermansen TS, Ravn P, Svensson E, Lillebaek T. Nontuberculous mycobacteria in Denmark, incidence and clinical importance during the last quarter-century. Sci Rep 2017; 7 (01) 6696
  • 5 Smith GS, Ghio AJ, Stout JE. , et al. Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006-2010. J Infect 2016; 72 (06) 678-686
  • 6 Blanc P, Dutronc H, Peuchant O. , et al. Nontuberculous mycobacterial infections in a French hospital: a 12-year retrospective study. PLoS One 2016; 11 (12) e0168290
  • 7 Brode SK, Marchand-Austin A, Jamieson FB, Marras TK. Pulmonary versus nonpulmonary nontuberculous mycobacteria, Ontario, Canada. Emerg Infect Dis 2017; 23 (11) 1898-1901
  • 8 Henkle E, Hedberg K, Schafer SD, Winthrop KL. Surveillance of extrapulmonary nontuberculous mycobacteria infections, Oregon, USA, 2007-2012. Emerg Infect Dis 2017; 23 (10) 1627-1630
  • 9 Wentworth AB, Drage LA, Wengenack NL, Wilson JW, Lohse CM. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study. Mayo Clin Proc 2013; 88 (01) 38-45
  • 10 Tumbarello M, Tacconelli E, de Donati KG. , et al. Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies. Eur J Clin Microbiol Infect Dis 2001; 20 (07) 498-501
  • 11 Varley CD, Ku JH, Henkle E, Schafer SD, Winthrop KL. Disseminated nontuberculous mycobacteria in HIV-infected patients, Oregon, USA, 2007-2012. Emerg Infect Dis 2017; 23 (03) 533-535
  • 12 Horsburgh Jr CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324 (19) 1332-1338
  • 13 Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994; 170 (06) 1601-1605
  • 14 Chaisson RE, Benson CA, Dube MP. , et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121 (12) 905-911
  • 15 Dubé MP, Sattler FR, Torriani FJ. , et al; California Collaborative Treatment Group. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997; 176 (05) 1225-1232
  • 16 Benson CA, Williams PL, Currier JS. , et al; AIDS Clinical Trials Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37 (09) 1234-1243
  • 17 Gordin FM, Sullam PM, Shafran SD. , et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28 (05) 1080-1085
  • 18 Kobayashi T, Nishijima T, Teruya K. , et al. High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era. PLoS One 2016; 11 (03) e0151682
  • 19 Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5 (06) 361-373
  • 20 Phillips P, Bonner S, Gataric N. , et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41 (10) 1483-1497
  • 21 Sampaio EP, Bax HI, Hsu AP. , et al. A novel STAT1 mutation associated with disseminated mycobacterial disease. J Clin Immunol 2012; 32 (04) 681-689
  • 22 Yin SM, Ferdman RM, Wang L, Markert ML, Tam JS. Disseminated Mycobacterium kansasii disease in complete DiGeorge syndrome. J Clin Immunol 2015; 35 (05) 435-438
  • 23 Bennett C, Vardiman J, Golomb H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 1986; 80 (05) 891-896
  • 24 Biggs HM, Chudgar SM, Pfeiffer CD, Rice KR, Zaas AK, Wolfe CR. Disseminated Mycobacterium immunogenum infection presenting with septic shock and skin lesions in a renal transplant recipient. Transpl Infect Dis 2012; 14 (04) 415-421
  • 25 Brode SK, Jamieson FB, Ng R. , et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 2015; 70 (07) 677-682
  • 26 Tahara M, Yatera K, Yamasaki K. , et al. Disseminated Mycobacterium abscessus complex infection manifesting as multiple areas of lymphadenitis and skin abscess in the preclinical stage of acute lymphocytic leukemia. Intern Med 2016; 55 (13) 1787-1791
  • 27 Green L, Coumbe A, Sawicka E, De Lord C. Mycobacterium kansasii in a patient with hairy cell leukaemia. Br J Haematol 2009; 144 (01) 2
  • 28 Lovell JP, Zerbe CS, Olivier KN. , et al. Mediastinal and disseminated Mycobacterium kansasii disease in GATA2 deficiency. Ann Am Thorac Soc 2016; 13 (12) 2169-2173
  • 29 Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15 (10) 1556-1561
  • 30 Winthrop KL, Baxter R, Liu L. , et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72 (01) 37-42
  • 31 Chi CY, Lin CH, Ho MW. , et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore) 2016; 95 (25) e3927
  • 32 Aoki A, Sakagami T, Yoshizawa K. , et al. Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis 2017
  • 33 Czaja CA, Merkel PA, Chan ED. , et al. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody. Clin Infect Dis 2014; 58 (06) e115-e118
  • 34 Chang CY, Tsay RW, Lin LC, Liu CE. Venous catheter-associated bacteremia caused by rapidly growing mycobacteria at a medical center in central Taiwan. J Microbiol Immunol Infect 2009; 42 (04) 343-350
  • 35 Tortoli E, Rindi L, Garcia MJ. , et al. Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov. Int J Syst Evol Microbiol 2004; 54 (Pt 4): 1277-1285
  • 36 Achermann Y, Rössle M, Hoffmann M. , et al. Prosthetic valve endocarditis and bloodstream infection due to Mycobacterium chimaera . J Clin Microbiol 2013; 51 (06) 1769-1773
  • 37 Sax H, Bloemberg G, Hasse B. , et al. Prolonged outbreak of Mycobacterium chimaera infection after open-chest heart surgery. Clin Infect Dis 2015; 61 (01) 67-75
  • 38 Sommerstein R, Rüegg C, Kohler P, Bloemberg G, Kuster SP, Sax H. Transmission of Mycobacterium chimaera from heater-cooler units during cardiac surgery despite an ultraclean air ventilation system. Emerg Infect Dis 2016; 22 (06) 1008-1013
  • 39 Svensson E, Jensen ET, Rasmussen EM, Folkvardsen DB, Norman A, Lillebaek T. Mycobacterium chimaera in heater-cooler units in Denmark related to isolates from the United States and United Kingdom. Emerg Infect Dis 2017; 23 (03) 507-509
  • 40 Haller S, Höller C, Jacobshagen A. , et al. Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. Euro Surveill 2016; 21 (17) 21
  • 41 Garvey MI, Ashford R, Bradley CW. , et al. Decontamination of heater-cooler units associated with contamination by atypical mycobacteria. J Hosp Infect 2016; 93 (03) 229-234
  • 42 Götting T, Klassen S, Jonas D. , et al. Heater-cooler units: contamination of crucial devices in cardiothoracic surgery. J Hosp Infect 2016; 93 (03) 223-228
  • 43 Allen KB, Yuh DD, Schwartz SB. , et al. Nontuberculous mycobacterium infections associated with heater-cooler devices. Ann Thorac Surg 2017; 104 (04) 1237-1242
  • 44 Kohler P, Kuster SP, Bloemberg G. , et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery. Eur Heart J 2015; 36 (40) 2745-2753
  • 45 Chand M, Lamagni T, Kranzer K. , et al. Insidious risk of severe Mycobacterium chimaera infection in cardiac surgery patients. Clin Infect Dis 2017; 64 (03) 335-342
  • 46 Zweifel SA, Mihic-Probst D, Curcio CA. , et al. Clinical and histopathologic ocular findings in disseminated Mycobacterium chimaera infection after cardiothoracic surgery. Ophthalmology 2017; 124 (02) 178-188
  • 47 Cheng A, Sheng WH, Huang YC. , et al. Prolonged postprocedural outbreak of Mycobacterium massiliense infections associated with ultrasound transmission gel. Clin Microbiol Infect 2016; 22 (04) 382.e1-382.e11
  • 48 Rodriguez JM, Xie YL, Winthrop KL. , et al. Mycobacterium chelonae facial infections following injection of dermal filler. Aesthet Surg J 2013; 33 (02) 265-269
  • 49 Ivan M, Dancer C, Koehler AP, Hobby M, Lease C. Mycobacterium chelonae abscesses associated with biomesotherapy, Australia, 2008. Emerg Infect Dis 2013; 19 (09) 1493-1495
  • 50 Galmés-Truyols A, Giménez-Duran J, Bosch-Isabel C. , et al. An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin 2011; 29 (07) 510-514
  • 51 Koh SJ, Song T, Kang YA. , et al. An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture. Clin Microbiol Infect 2010; 16 (07) 895-901
  • 52 Nash KA, Brown-Elliott BA, Wallace Jr RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae . Antimicrob Agents Chemother 2009; 53 (04) 1367-1376
  • 53 Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35 (04) 400-404
  • 54 van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012; 56 (12) 6324-6327
  • 55 Schnabel D, Gaines J, Nguyen DB. , et al; Centers for Disease Control and Prevention (CDC). Notes from the field: rapidly growing nontuberculous Mycobacterium wound infections among medical tourists undergoing cosmetic surgeries in the Dominican Republic--multiple states, March 2013-February 2014. MMWR Morb Mortal Wkly Rep 2014; 63 (09) 201-202
  • 56 Schnabel D, Esposito DH, Gaines J. , et al; RGM Outbreak Investigation Team. Multistate US outbreak of rapidly growing mycobacterial infections associated with medical tourism to the Dominican Republic, 2013-2014(1). Emerg Infect Dis 2016; 22 (08) 1340-1347
  • 57 Duarte RS, Lourenço MC, Fonseca LdeS. , et al. Epidemic of postsurgical infections caused by Mycobacterium massiliense . J Clin Microbiol 2009; 47 (07) 2149-2155
  • 58 Viana-Niero C, Lima KV, Lopes ML. , et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46 (03) 850-855
  • 59 Cardoso AM, Martins de Sousa E, Viana-Niero C. , et al. Emergence of nosocomial Mycobacterium massiliense infection in Goiás, Brazil. Microbes Infect 2008; 10 (14-15): 1552-1557
  • 60 Kluger N, Muller C, Gral N. Atypical mycobacteria infection following tattooing: review of an outbreak in 8 patients in a French tattoo parlor. Arch Dermatol 2008; 144 (07) 941-942
  • 61 Hamsch C, Hartschuh W, Enk A, Flux K. A Chinese tattoo paint as a vector of atypical mycobacteria-outbreak in 7 patients in Germany. Acta Derm Venereol 2011; 91 (01) 63-64
  • 62 Curcó N, Prat C, Tarroch X, Vives P. Cutaneous infection in a tattoo due to mycobacterium chelonae: a report of 2 cases and a review of the literature. Actas Dermosifiliogr 2012; 103 (09) 840-843
  • 63 Centers for Disease Control and Prevention (CDC). Tattoo-associated nontuberculous mycobacterial skin infections--multiple states, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61 (33) 653-656
  • 64 Sergeant A, Conaglen P, Laurenson IF. , et al. Mycobacterium chelonae infection: a complication of tattooing. Clin Exp Dermatol 2013; 38 (02) 140-142
  • 65 Goldman J, Caron F, de Quatrebarbes J. , et al. Infections from tattooing. Outbreak of Mycobacterium chelonae in France. BMJ 2010; 341: c5483
  • 66 Kennedy BS, Bedard B, Younge M. , et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med 2012; 367 (11) 1020-1024
  • 67 Nash KA, Zhang Y, Brown-Elliott BA, Wallace Jr RJ. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum . J Antimicrob Chemother 2005; 55 (02) 170-177
  • 68 Winthrop KL, Abrams M, Yakrus M. , et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med 2002; 346 (18) 1366-1371
  • 69 Winthrop KL, Albridge K, South D. , et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38 (01) 38-44
  • 70 Broutin V, Bañuls AL, Aubry A. , et al. Genetic diversity and population structure of Mycobacterium marinum: new insights into host and environmental specificities. J Clin Microbiol 2012; 50 (11) 3627-3634
  • 71 Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37 (03) 390-397
  • 72 Sia TY, Taimur S, Blau DM. , et al. Clinical and pathological evaluation of Mycobacterium marinum group skin infections associated with fish markets in New York City. Clin Infect Dis 2016; 62 (05) 590-595
  • 73 Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162 (15) 1746-1752
  • 74 Cheung JP, Fung B, Ip WY, Chow SP. Mycobacterium marinum infection of the hand and wrist. J Orthop Surg (Hong Kong) 2012; 20 (02) 214-218
  • 75 Johnson MG, Stout JE. Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review. Infection 2015; 43 (06) 655-662
  • 76 Wu TS, Chiu CH, Yang CH. , et al. Fish tank granuloma caused by Mycobacterium marinum . PLoS One 2012; 7 (07) e41296
  • 77 Eberst E, Dereure O, Guillot B. , et al. Epidemiological, clinical, and therapeutic pattern of Mycobacterium marinum infection: a retrospective series of 35 cases from southern France. J Am Acad Dermatol 2012; 66 (01) e15-e16
  • 78 Huang Y, Xu X, Liu Y. , et al. Successful treatment of refractory cutaneous infection caused by Mycobacterium marinum with a combined regimen containing amikacin. Clin Interv Aging 2012; 7: 533-538
  • 79 Hisamichi K, Hiruma M, Yamazaki M, Matsushita A, Ogawa H. Efficacy of oral minocycline and hyperthermic treatment in a case of atypical mycobacterial skin infection by Mycobacterium marinum . J Dermatol 2002; 29 (12) 810-811
  • 80 Clancey JK, Dodge OG, Lunn HF, Oduori ML. Mycobacterial skin ulcers in Uganda. Lancet 1961; 2 (7209): 951-954
  • 81 MacCallum CP, Tolhurst JC. , et al. A new mycobacterial infection in man. J Pathol Bacteriol 1948; 60: 93-122
  • 82 Yotsu RR, Murase C, Sugawara M. , et al. Revisiting Buruli ulcer. J Dermatol 2015; 42 (11) 1033-1041
  • 83 World Health Organization. Global health Observatory (GH0) data: Buruli ulcer. 2017 [cited November 21, 2017]; Available at: http://www.who.int/gho/neglected_diseases/buruli_ulcer/en/
  • 84 Käser M, Rondini S, Naegeli M. , et al. Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans . BMC Evol Biol 2007; 7: 177
  • 85 Vincent QB, Ardant MF, Adeye A. , et al. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. Lancet Glob Health 2014; 2 (07) e422-e430
  • 86 Steffen CM, Freeborn H. Mycobacterium ulcerans in the Daintree 2009-2015 and the mini-epidemic of 2011. ANZ J Surg 2016
  • 87 Stinear TP, Mve-Obiang A, Small PL. , et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans . Proc Natl Acad Sci U S A 2004; 101 (05) 1345-1349
  • 88 Hall B, Simmonds R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans 2014; 42 (01) 177-183
  • 89 Marion E, Song OR, Christophe T. , et al. Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. Cell 2014; 157 (07) 1565-1576
  • 90 Wadagni A, Frimpong M, Phanzu DM. , et al. Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography. PLoS Negl Trop Dis 2015; 9 (11) e0004247
  • 91 World Health Organization. Treatment of Mycobacterium ulcerans Disease (Buruli Ulcer): Guidance for Health Workers. Geneva: 2012
  • 92 Friedman ND, Athan E, Walton AL, O'Brien DP. Increasing experience with primary oral medical therapy for Mycobacterium ulcerans disease in an Australian cohort. Antimicrob Agents Chemother 2016; 60 (05) 2692-2695
  • 93 O'Brien DP, McDonald A, Callan P. , et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012; 6 (01) e1473
  • 94 O'Brien DP, Robson M, Friedman ND. , et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013; 13: 416
  • 95 Nienhuis WA, Stienstra Y, Abass KM. , et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54 (04) 519-526
  • 96 Ruf MT, Chauty A, Adeye A. , et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS Negl Trop Dis 2011; 5 (08) e1252
  • 97 Izawa K, Kitada S. Clinical analysis of osteoarticular nontuberculous mycobacterial infection. Kekkaku 2016; 91 (01) 1-8
  • 98 Kobayashi T, Morino E, Takasaki J, Nagahara Y, Sugiyama H. Nontuberculous mycobacterial osteomyelitis in human immunodeficiency virus-negative patients: a case series. Jpn J Infect Dis 2016; 69 (02) 149-150
  • 99 Park JW, Kim YS, Yoon JO. , et al. Non-tuberculous mycobacterial infection of the musculoskeletal system: pattern of infection and efficacy of combined surgical/antimicrobial treatment. Bone Joint J 2014; 96-B (11) 1561-1565
  • 100 Hogan JI, Hurtado RM, Nelson SB. Mycobacterial musculoskeletal infections. Infect Dis Clin North Am 2017; 31 (02) 369-382
  • 101 Lee EY, Rubin DA, Brown DM. Recurrent Mycobacterium marinum tenosynovitis of the wrist mimicking extraarticular synovial chondromatosis on MR images. Skeletal Radiol 2004; 33 (07) 405-408
  • 102 Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL. Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing. Clin Infect Dis 2000; 30 (03) 444-453
  • 103 Vasireddy R, Vasireddy S, Brown-Elliott BA. , et al. Mycobacterium arupense, Mycobacterium heraklionense, and a newly proposed species, “Mycobacterium virginiense” sp. nov., but not Mycobacterium nonchromogenicum, as species of the Mycobacterium terrae complex causing tenosynovitis and osteomyelitis. J Clin Microbiol 2016; 54 (05) 1340-1351
  • 104 Unai S, Miessau J, Karbowski P, Bajwa G, Hirose H. Sternal wound infection caused by Mycobacterium chelonae . J Card Surg 2013; 28 (06) 687-692
  • 105 Hoffman PC, Fraser DW, Robicsek F, O'Bar PR, Mauney CU. Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143 (04) 533-542
  • 106 Ingraham NE, Schneider B, Alpern JD. Prosthetic joint infection due to Mycobacterium avium-intracellulare in a patient with rheumatoid arthritis: a case report and review of the literature. Case Rep Infect Dis 2017; 2017: 8682354
  • 107 Henry MW, Miller AO, Kahn B, Windsor RE, Brause BD. Prosthetic joint infections secondary to rapidly growing mycobacteria: two case reports and a review of the literature. Infect Dis (Lond) 2016; 48 (06) 453-460
  • 108 Rahal A, Abela A, Arcand PH, Quintal MC, Lebel MH, Tapiero BF. Nontuberculous mycobacterial adenitis of the head and neck in children: experience from a tertiary care pediatric center. Laryngoscope 2001; 111 (10) 1791-1796
  • 109 Panesar J, Higgins K, Daya H, Forte V, Allen U. Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review. Laryngoscope 2003; 113 (01) 149-154
  • 110 Haverkamp MH, Arend SM, Lindeboom JA, Hartwig NG, van Dissel JT. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004; 39 (04) 450-456
  • 111 Thegerström J. Pinpointing the source of infection of Mycobacterium avium hominissuis in children. Infect Dis (Lond) 2017; 49 (08) 617-624
  • 112 Ding LW, Lai CC, Lee LN, Huang LM, Hsueh PR. Lymphadenitis caused by non-tuberculous mycobacteria in a university hospital in Taiwan: predominance of rapidly growing mycobacteria and high recurrence rate. J Formos Med Assoc 2005; 104 (12) 897-904
  • 113 Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44 (08) 1057-1064
  • 114 Lindeboom JA, Lindeboom R, Bruijnesteijn van Coppenraet ES, Kuijper EJ, Tuk J, Prins JM. Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Infect Dis J 2009; 28 (11) 1028-1030
  • 115 Lindeboom JA. Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children. J Oral Maxillofac Surg 2012; 70 (02) 345-348
  • 116 Blyth CC, Best EJ, Jones CA. , et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28 (09) 801-805
  • 117 Lindeboom JA. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2011; 52 (02) 180-184
  • 118 Zimmermann P, Tebruegge M, Curtis N, Ritz N. The management of non-tuberculous cervicofacial lymphadenitis in children: a systematic review and meta-analysis. J Infect 2015; 71 (01) 9-18
  • 119 Gonzalez CD, Petersen MG, Miller M, Park AH, Wilson KF. Complex nontuberculous mycobacterial cervicofacial lymphadenitis: what is the optimal approach?. Laryngoscope 2016; 126 (07) 1677-1680
  • 120 Hatzenbuehler LA, Tobin-D'Angelo M, Drenzek C. , et al. Pediatric dental clinic-associated outbreak of Mycobacterium abscessus infection. J Pediatric Infect Dis Soc 2017; 6 (03) e116-e122
  • 121 Girgis DO, Karp CL, Miller D. Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management. Clin Experiment Ophthalmol 2012; 40 (05) 467-475
  • 122 Brown-Elliott BA, Mann LB, Hail D, Whitney C, Wallace Jr RJ. Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections. Cornea 2012; 31 (08) 900-906
  • 123 Moorthy RS, Valluri S, Rao NA. Nontuberculous mycobacterial ocular and adnexal infections. Surv Ophthalmol 2012; 57 (03) 202-235
  • 124 Kheir WJ, Sheheitli H, Abdul Fattah M, Hamam RN. Nontuberculous mycobacterial ocular infections: a systematic review of the literature. BioMed Res Int 2015; 2015: 164989
  • 125 Nascimento H, Viana-Niero C, Nogueira CL. , et al. Identification of the infection source of an outbreak of Mycobacterium Chelonae keratitis after laser in situ keratomileusis. Cornea 2018; 37 (01) 116-122
  • 126 Holmes GP, Bond GB, Fader RC, Fulcher SF. A cluster of cases of Mycobacterium szulgai keratitis that occurred after laser-assisted in situ keratomileusis. Clin Infect Dis 2002; 34 (08) 1039-1046
  • 127 Chandra NS, Torres MF, Winthrop KL. , et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am J Ophthalmol 2001; 132 (06) 819-830
  • 128 Freitas D, Alvarenga L, Sampaio J. , et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology 2003; 110 (02) 276-285
  • 129 Yamaguchi T, Bissen-Miyajima H, Hori-Komai Y. , et al. Infectious keratitis outbreak after laser in situ keratomileusis at a single laser center in Japan. J Cataract Refract Surg 2011; 37 (05) 894-900
  • 130 Chu HS, Hu FR. Non-tuberculous mycobacterial keratitis. Clin Microbiol Infect 2013; 19 (03) 221-226
  • 131 Dolz-Marco R, Udaondo P, Gallego-Pinazo R, Millán JM, Díaz-Llopis M. Topical linezolid for refractory bilateral Mycobacterium chelonae post-laser-assisted in situ keratomileusis keratitis. Arch Ophthalmol 2012; 130 (11) 1475-1476
  • 132 Aung TT, Chor WHJ, Yam JKH, Givskov M, Yang L, Beuerman RW. Discovery of novel antimycobacterial drug therapy in biofilm of pathogenic nontuberculous mycobacterial keratitis. Ocul Surf 2017; 15 (04) 770-783
  • 133 Hung JH, Huang YH, Chang TC. , et al. A cluster of endophthalmitis caused by Mycobacterium abscessus after cataract surgery. J Microbiol Immunol Infect 2016; 49 (05) 799-803